FGG

FGG encodes the fibrinogen gamma chain, a subunit required for both intracellular assembly of the fibrinogen hexamer and its secretion as a functional clotting factor (PMID:15284111, PMID:16141000). The C-terminal globular domain of the gamma chain is functionally partitioned: it is required for hexamer assembly (PMID:15284111), while distinct determinants within the same domain govern secretion independently of assembly, since a globular-domain missense mutation permits intracellular assembly yet abolishes secretion (PMID:16141000). Once secreted, the gamma chain contributes the 'A:a' knob-hole interaction and conformational determinants needed for thrombin-catalyzed fibrin polymerization and normal clot architecture, and point mutations in this region produce dysfunctional polymerization, altered clot ultrastructure, and prolonged fibrinolysis (PMID:35067535, PMID:38233949). Loss-of-function alleles cause quantitative deficiency through several routes: nonsense mutations bearing premature stop codons trigger nonsense-mediated mRNA decay (PMID:24011387), and splice-site, deep-intronic, and junction-duplication mutations generate aberrant transcripts that lose normal gamma-chain (and gamma'-chain) production, causing hypofibrinogenemia and congenital afibrinogenemia (PMID:20580695, PMID:27837696, PMID:34196169). Hepatic FGG expression is controlled by PFE2, a liver-specific enhancer located between FGA and FGG (PMID:22836734). Beyond hemostasis, FGG promotes tumor cell migration and invasion via EMT through Slug and ZEB1 upregulation (PMID:30863175), and drives liver fibrosis by activating hepatic stellate cells and promoting M2 macrophage polarization (PMID:42001119).

1. 2004 Medium

   Established that the gamma-chain C-terminal region is required for assembly of fibrinogen into a functional hexamer, distinguishing assembly defects from transcript-level defects.

   Evidence Expression of a nonsense mutant (Arg134Xaa) FGG cDNA in COS-7 cells with mRNA stability and protein assembly readouts

   PMID:15284111

   Open questions at the time

   • Does not map the precise residues mediating chain-chain contacts
   • Single cell-based system without structural confirmation
2. 2005 Medium

   Resolved that secretion of assembled fibrinogen is governed by determinants in the gamma-chain globular domain that are separable from assembly determinants.

   Evidence Co-expression of W253C mutant FGG with wild-type FGA and FGB in cells; ELISA of media versus lysates

   PMID:16141000

   Open questions at the time

   • Mechanism of the secretion block (folding, trafficking, retention) not defined
   • Single missense allele
3. 2006 Low

   Linked a specific gamma-chain residue substitution to defective thrombin-catalyzed polymerization at the level of clot formation.

   Evidence Polymerization analysis of purified fibrinogen from a patient (Fibrinogen Seoul, Ala341Asp) plus molecular modeling

   PMID:16959688

   Open questions at the time

   • Single method on a single patient sample without recombinant validation
   • Conformational change inferred from modeling, not measured
4. 2010 Medium

   Showed that splice-site mutations produce aberrant gamma-chain transcripts as a route to hypofibrinogenemia, beyond coding-region defects.

   Evidence Minigene transfection of IVS3-2A>G in CHO cells; RT-PCR of mRNA products

   PMID:20580695

   Open questions at the time

   • Does not quantify protein-level consequences
   • Fate of aberrant transcripts (NMD vs. translation) not addressed
5. 2012 Medium

   Identified the cis-regulatory basis of liver-specific FGG expression by characterizing the intergenic PFE2 enhancer.

   Evidence Luciferase reporter assays in hepatoma cells and transgenic zebrafish in vivo enhancer assay with ChIP-seq integration

   PMID:22836734

   Open questions at the time

   • Transcription factors binding PFE2 not identified
   • Contribution to FGG versus FGA regulation not separated
6. 2013 High

   Demonstrated that premature-stop-codon FGG alleles cause deficiency through nonsense-mediated mRNA decay, not solely defective protein.

   Evidence Minigene transfection in CHO cells with cycloheximide rescue, qRT-PCR, immunoblot, and ELISA

   PMID:24011387

   Open questions at the time

   • Allele-specific contribution of NMD versus protein instability not quantified per variant
   • In vivo confirmation in patient hepatocytes absent
7. 2016 Medium

   Extended the deficiency mechanism to deep-intronic and junction deletions and identified the Ex-9 region as required for normal gamma'-chain regulation.

   Evidence Minigene transfection and stable recombinant CHO cell lines; RT-PCR and Western blot of gammaA and gamma' chains

   PMID:27837696

   Open questions at the time

   • Functional consequence of augmented gamma'-chain secretion not assessed
   • Mechanism by which Ex-9 controls gamma' splicing not defined
8. 2019 Medium

   Established a non-hemostatic, pro-metastatic role for FGG in driving EMT-dependent tumor cell migration and invasion.

   Evidence FGG overexpression and siRNA knockdown in SK-HEP-1 cells; transwell/wound healing assays; Western blot for Slug and ZEB1

   PMID:30863175

   Open questions at the time

   • Direct molecular link between FGG and Slug/ZEB1 induction not defined
   • In vivo metastasis not tested
9. 2020 Low

   Implicated FGG in anthracycline chemoresistance and cancer stem cell traits in breast cancer.

   Evidence FGG overexpression/knockdown in chemoresistant breast cancer lines with JAK2/STAT3 pharmacological inhibition and viability/stemness assays

   PMID:32266101

   Open questions at the time

   • JAK2/STAT3 placement relies on inhibitor without direct FGG-pathway interaction
   • Single lab, not independently confirmed
10. 2022 Medium

    Confirmed that a junction-duplicating mutation generates premature-stop transcripts causing congenital afibrinogenemia, reinforcing aberrant-splicing as a deficiency mechanism.

    Evidence Minigene transfection, mRNA analysis, and whole exome sequencing with PCR confirmation of a 403 bp exon 8-intron 8 duplication

    PMID:34196169

    Open questions at the time

    • NMD versus truncated-protein contribution not directly tested
    • Single family
11. 2022 Medium

    Connected a signal-peptide-region mutation to altered fibrin polymerization, clot ultrastructure, fibrinolysis, and oxidative PTMs in a thrombosis-associated hypofibrinogenemia.

    Evidence Fibrin polymerization and fibrinolysis assays, SEM clot imaging, and mass spectrometry PTM detection on patient fibrinogen

    PMID:35067535

    Open questions at the time

    • Causal link between signal-peptide variant and oxidative PTMs unresolved
    • Single case
12. 2024 Medium

    Mapped a missense variant to the 'A:a' knob-hole interaction, mechanistically tying a structural contact to impaired synthesis, secretion, and polymerization.

    Evidence Recombinant fibrinogen CHO cell lines with Western blot, ELISA, thrombin-catalyzed polymerization, and in silico structural analysis of c.1168G>T

    PMID:38233949

    Open questions at the time

    • Structural disruption inferred in silico, not by experimental structure
    • Single variant
13. 2026 Medium

    Defined an active role for FGG in liver fibrosis through hepatic stellate cell activation and M2 macrophage polarization, identifying it as a therapeutic target.

    Evidence BDL mouse model, LX2-THP-1 co-culture, FGG overexpression mice, and AEAA-LNP siRNA knockdown with multi-omic and imaging readouts

    PMID:42001119

    Open questions at the time

    • Direct molecular receptor/effector mediating HSC-macrophage crosstalk not identified
    • Single lab

• How the gamma chain's hemostatic role mechanistically connects to its pro-fibrotic and pro-tumorigenic signaling functions remains unresolved.
• No cell-surface receptor for FGG signaling identified
• No structural model of full-length gamma chain in the corpus
• Transcription factors controlling PFE2 enhancer unknown